Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood- United States

doi 10.1182/blood.v120.21.43.43

Full Text

Abstract

Available in

Date

November 16, 2012

Authors

Guillermo Garcia-Manero

Publisher

American Society of Hematology

Related search

Idarubicin, Cytarabine and Pravastatin as Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

English

Clofarabine Combinations as Acute Myeloid Leukemia Salvage Therapy

English

Phase II Trial of Clofarabine and Daunorubicin as Induction Therapy for Acute Myeloid Leukemia Patients Greater Than or Equal to 60 Years of Age

English

Intesive Fludarabine-High Dose Cytarabine-Idarubicin Combination as Induction Therapy With Risk-Adapted Consolidation May Improve Treatment Efficacy in Younger Acute Myeloid Leukemia (AML) Patients: Rationales, Evidences and Future Perspectives

English

Cytarabine Dose for Acute Myeloid Leukemia

New England Journal of Medicine

Medicine

2011

English

Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia

English

Sorafenib as Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia

English

Decitabine Compared With Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

Advances in Hematology

Hematology

2015

English

Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia

English

Amanote Research

Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Idarubicin, Cytarabine and Pravastatin as Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Clofarabine Combinations as Acute Myeloid Leukemia Salvage Therapy

Phase II Trial of Clofarabine and Daunorubicin as Induction Therapy for Acute Myeloid Leukemia Patients Greater Than or Equal to 60 Years of Age

Intesive Fludarabine-High Dose Cytarabine-Idarubicin Combination as Induction Therapy With Risk-Adapted Consolidation May Improve Treatment Efficacy in Younger Acute Myeloid Leukemia (AML) Patients: Rationales, Evidences and Future Perspectives

Cytarabine Dose for Acute Myeloid Leukemia

Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia

Sorafenib as Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia

Decitabine Compared With Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia